FibroGen Inc. Enters Restructuring Mode After Late-Stage Trial Failures for Pamrevlumab
US-based biotechnology company FibroGen Inc. (NASDAQ: FGEN), which maintains significant operations in China, is initiating...
National Comprehensive Cancer Network Renews Partnership with Medlive for Oncology Guidelines Access in China
The National Comprehensive Cancer Network (NCCN), a leading non-profit academic organization in the US, has...
China’s NHSA and NHC to Integrate Village Clinics into Basic Medical Insurance System
The National Healthcare Security Administration (NHSA) and the National Health Commission (NHC) of China have...
Shenzhen-Based Synthetica Secures Initial Funding to Advance Oncolytic Bacteria Pipeline
Synthetica, a pioneering developer of live bacteria drugs based in Shenzhen, has announced the successful...
China’s NMPA Approves Pilot Plan to Streamline Clinical Trial Reviews for Innovative Drugs
In a meeting chaired by Party Secretary and Director of the National Medical Products Administration...
Bio-Thera Solutions’ Bevacizumab Biosimilar Avzivi Receives European Commission Approval
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that its biosimilar version of Roche’s Avastin, Avzivi...
Gan & Lee Pharmaceuticals Gains Market Foothold in Algeria with Insulin Product Approvals
Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has...
MicroPort Scientific’s Fully Biodegradable Cardiac Stent Earns NMPA Nod
Shanghai-based medical device titan MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...
Suzhou Hanerxi Medical Secures Series B Funding to Build Asia’s Largest Pen Injector Facility
Suzhou Hanerxi Medical Device Development Co., Ltd, a specialist in pen syringe technology based in...
Brii Bioscience’s US Partner VBI Vaccines Initiates Bankruptcy Reorganization
Brii Biosciences Ltd (HKG: 2137), a biopharmaceutical company based in China, has announced that its...
Cutia Therapeutics’ CU-30101 NDA Accepted for Review by China’s NMPA
Cutia Therapeutics (HKG: 2487), a company specializing in dermatological treatments, has announced that the National...
China’s NMPA Issues Guidelines for Onsite Inspections of Medical Device Companies
The National Medical Products Administration (NMPA) of China has released the “Guidelines for Onsite Inspection...
WuXi AppTec’s H1 2024 Financials Reflect Decline Amid Biosecure Act Challenges
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec (HKG: 2359) has reported a subdued...
Roche Completes Acquisition of LumiraDx’s Point-of-Care Solutions Business
Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG, OTCMKTS: RHHBY, SWX: RO) has announced the...
Philips Posts 2% Q2 2024 Sales Growth, Boosted by North American Demand
Royal Philips (NYSE: PHG), the Dutch electronics giant, reported its financial results for the second...
GSK Enters into Strategic Partnership with Flagship Pioneering to Develop Novel Medicines and Vaccines
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK, LON: GSK) has announced a new partnership with...
Novartis’s Scemblix Receives FDA Priority Review for First-Line CML Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the US Food and Drug Administration...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-A1921 Clinical Study in Advanced Solid Tumors
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Porton Pharma Solutions Partners with Guangzhou Geneseed Biotech to Advance circRNA Therapies
Porton Pharma Solutions Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...
ShuWen Biotech’s Preeclampsia Self-Test Receives NMPA Approval, Marking a Global First
Zhejiang-based ShuWen Biotech Co., Ltd has announced that it has received marketing approval from China’s...